News

John McManus, Chief Executive Officer, presented an outline of Aeolus’ development programs with a focus on the company’s progress regarding its contract with the Biomedical Advanced Research and Development Authority (“BARDA”), during the LD Micro Invitational meeting that took place last December in Los Angeles. The details of that meeting were recently…

Building a new set of lungs for patients with pulmonary fibrosis is becoming closer to reality as a result of cutting-edge research in the field of tissue engineering. At the forefront of this endeavor is Cheryl Nickerson, PhD, an expert in infectious diseases and vaccinology at Arizona State University Biodesign Institute.

RestorGenex Pharmaceuticals, a biotechnology company developing innovative therapeutics for a large spectrum of diseases, including cancer and those of the dermatology and ophthalmology spectrum, recently presented at the American Thoracic Society International Conference in Denver, Colorado their latest results using RES-529 as a potential treatment for idiopathic pulmonary fibrosis.

Veracyte, Inc. a biotechnology company working in the field of molecular cytology, recently presented new results showing that its molecular classifier can distinguish idiopathic pulmonary fibrosis (IPF) from other interstitial lung diseases (ILDs) in bronchoscopy-derived samples. The results indicate that the molecular classifier is able to help patients avoid invasive,…

During the 2015 American Thoracic Society Conference (ATS), Genentech presented new data on Esbriet (pirfenidone) — one of the first medicines approved by the US Food and Drug Administration to treat idiopathic pulmonary fibrosis (IPF), a serious disease of unknown origins that causes permanent scarring of the lungs.

Boehringer Ingelheim recently announced positive results regarding the safety, tolerability and efficacy of FDA-approved OFEV® (nintedanib*) in patients with idiopathic pulmonary fibrosis (IPF). The results were recently presented during the 2015 International Conference of the American Thoracic Society (ATS), which took place in Denver, and reveal continued long-term effectiveness in…

The Hastings Foundation has announced that it is going to grant $7.5 million in support to the University of South California (USC) for the creation of the Hastings Center for Pulmonary Research (HCPR) at Keck Medicine of USC. The grant will be spread across five years with the main purpose on improving research…

The Pulmonary Fibrosis Foundation (PFF) recently expressed its sadness over the loss of PFF Ambassador Diane Reichert, who has passed away. Diane received a diagnosis of idiopathic pulmonary fibrosis (IPF) in 2013, after which she became an Ambassador for the Foundation to help assist and raise awareness about her own disease. According to…

Boehringer Ingelheim Pharmaceuticals, Inc. recently announced in a press release that the company will present 29 abstracts on respiratory disorders at the 2015 American Thoracic Society (ATS) International Conference in Denver, May 15-20. The company will present the latest data on their investigational drug portfolio for disorders like chronic…

Hard at work in the laboratory of Dr. Christine Kim Garcia, Associate Professor of Internal Medicine at UT Southwestern Medical Center, is a group of researchers studying familial pulmonary fibrosis. The disease is characterized by fatal lung scarring and is now associated with mutations in two genes: PARN and RTEL1.